drugset
drugset / Trial / NCT07394725

Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management

NCT07394725 ↗

Phase 1 Completed 250 enrolled District Headquarters Teaching Hospital Sahiwal
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized controlled trial at Sahiwal Teaching Hospital (April 2024-March 2025) compared azithromycin and erythromycin for managing preterm premature rupture of membranes (PPROM) in 250 women (28-33+6 weeks gestation). Participants received either azithromycin 500 mg once daily or erythromycin 250 mg every six hours for seven days.

Timeline

Start
2024-04-01
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg Oral
Subject Erythromycin Small molecule 250 mg Oral

Indications

preterm premature rupture of the membranes